EE200200531A - Terapeutiliste rakkusisenevate antikehade saamineja kasutamine - Google Patents

Terapeutiliste rakkusisenevate antikehade saamineja kasutamine

Info

Publication number
EE200200531A
EE200200531A EEP200200531A EEP200200531A EE200200531A EE 200200531 A EE200200531 A EE 200200531A EE P200200531 A EEP200200531 A EE P200200531A EE P200200531 A EEP200200531 A EE P200200531A EE 200200531 A EE200200531 A EE 200200531A
Authority
EE
Estonia
Prior art keywords
production
intracellular antibodies
therapeutic
therapeutic intracellular
antibodies
Prior art date
Application number
EEP200200531A
Other languages
English (en)
Inventor
Valkna Andres
Kogerman Priit
Original Assignee
O� InBio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O� InBio filed Critical O� InBio
Priority to EEP200200531A priority Critical patent/EE200200531A/et
Priority to CA002499321A priority patent/CA2499321A1/en
Priority to EP03797197A priority patent/EP1539823A1/en
Priority to AU2003266225A priority patent/AU2003266225A1/en
Priority to PCT/EE2003/000005 priority patent/WO2004026911A1/en
Priority to US10/528,073 priority patent/US20080063633A1/en
Publication of EE200200531A publication Critical patent/EE200200531A/et

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200531A 2002-09-17 2002-09-17 Terapeutiliste rakkusisenevate antikehade saamineja kasutamine EE200200531A (et)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EEP200200531A EE200200531A (et) 2002-09-17 2002-09-17 Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
CA002499321A CA2499321A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
EP03797197A EP1539823A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
AU2003266225A AU2003266225A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
PCT/EE2003/000005 WO2004026911A1 (en) 2002-09-17 2003-09-16 Obtaining and use of therapeutic antibodies entering into the cell
US10/528,073 US20080063633A1 (en) 2002-09-17 2003-09-16 Obtaining and Use of Therapeutic Antibodies Entering Into the Cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EEP200200531A EE200200531A (et) 2002-09-17 2002-09-17 Terapeutiliste rakkusisenevate antikehade saamineja kasutamine

Publications (1)

Publication Number Publication Date
EE200200531A true EE200200531A (et) 2004-04-15

Family

ID=32010907

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200531A EE200200531A (et) 2002-09-17 2002-09-17 Terapeutiliste rakkusisenevate antikehade saamineja kasutamine

Country Status (6)

Country Link
US (1) US20080063633A1 (et)
EP (1) EP1539823A1 (et)
AU (1) AU2003266225A1 (et)
CA (1) CA2499321A1 (et)
EE (1) EE200200531A (et)
WO (1) WO2004026911A1 (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
JP2015512246A (ja) * 2012-03-15 2015-04-27 パーミオン バイオロジクス， インコーポレイテッド 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734827B2 (en) * 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
SE9902899D0 (sv) * 1999-08-13 1999-08-13 Karolinska Innovations Ab New peptides, corresponding antibodies, and compositions thereof

Also Published As

Publication number Publication date
CA2499321A1 (en) 2004-04-01
US20080063633A1 (en) 2008-03-13
WO2004026911A1 (en) 2004-04-01
EP1539823A1 (en) 2005-06-15
AU2003266225A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
CY2015015I1 (el) Παραγωγη τιακουμυκινης
IL209010A0 (en) Use of tnfalpha antibodies and another drug
DK1513873T3 (da) Terapeutiske epitoper og anvendelser deraf
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DE60324099D1 (de) Arzneistoffhaltiger tampon
EP1482984A4 (en) REPLACEMENT ANTIBODIES AND METHOD FOR THEIR MANUFACTURE AND USE
IS7725A (is) Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra
MA28802B1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EE05505B1 (et) Personaalne teraapiasektsioon
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
NO20050689L (no) Terapeutisk anvendelse
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DE60238174D1 (de) Fluoropolymere und Herstellungs- und Verwendungsverfahren
HK1099699A1 (en) Therapeutic use of anti-cs1 antibodies
EE200200531A (et) Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
NO20034172D0 (no) Bisykliske guanidinderivater og terapeutiske anvendelser derav
DE60316792D1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
FI20020360A0 (fi) Biologisesti aktiivisen tuotteen uusi käyttö
ITMI20041962A1 (it) "peptide di angiostatina e suoi impieghio terapeutici"
DE60326437D1 (de) Therapeutische verwendung von sapogeninen